Selank vs Semax vs Dihexa: Three Approaches to Cognitive Enhancement Research
The comparison of Selank vs Semax vs Dihexa examines three of the most studied nootropic peptides, each operating through distinct neurological mechanisms. Selank modulates GABAergic neurotransmission for anxiolytic effects. Semax enhances BDNF expression and monoamine signaling for cognitive enhancement. Dihexa promotes synaptogenesis through the HGF/c-Met pathway. Understanding their differences is essential for designing targeted cognitive research protocols.
Explore Semax and our full research peptide catalog. Visit the research hub for more guides.
Selank: The Anxiolytic GABA Modulator
Structure and Origin
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the endogenous tetrapeptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been approved as an anxiolytic medication in Russia since 2009.
Mechanism of Action
- GABA-A receptor allosteric modulation: Enhances GABAergic inhibitory neurotransmission without direct receptor agonism, producing anxiolytic effects distinct from benzodiazepines
- Serotonin modulation: Increases serotonin and 5-HIAA levels in brain regions associated with mood regulation
- Enkephalin stabilization: Inhibits enkephalin-degrading enzymes, prolonging endogenous opioid peptide activity
- Gene expression: Microarray analysis shows Selank modulates 36+ genes related to inflammation, immune function, and neurotransmission (Inozemtseva et al., 2008)
Cognitive Profile
Selank’s cognitive effects are primarily secondary to anxiety reduction — by alleviating excessive anxiety-driven cognitive interference, Selank allows baseline cognitive performance to emerge. It does not typically enhance cognition beyond normal baseline in non-anxious subjects.
Semax: The BDNF-Boosting Nootropic
Structure and Origin
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of ACTH(4-7) with a stabilizing Pro-Gly-Pro C-terminal extension. Also developed at Russian Academy of Sciences institutes, Semax is approved in Russia for stroke treatment and cognitive enhancement.
Mechanism of Action
- BDNF upregulation: Semax significantly increases brain-derived neurotrophic factor expression in the hippocampus and cortex — the primary growth factor supporting neuronal survival, synaptic plasticity, and long-term potentiation (LTP) (Dolotov et al., 2006)
- TrkB receptor activation: BDNF-mediated activation of TrkB receptors triggers downstream PI3K/Akt and MAPK/ERK signaling cascades that support neuronal growth and synaptogenesis
- Monoamine modulation: Increases dopamine and serotonin turnover in the striatum and nucleus accumbens, enhancing motivation and cognitive processing
- Neuroprotection: Reduces excitotoxic damage through modulation of NMDA receptor activity; demonstrated neuroprotective effects in ischemic stroke models
Cognitive Profile
Semax produces direct cognitive enhancement — improved memory consolidation, faster learning acquisition, enhanced attention, and increased mental energy. These effects are BDNF-mediated and occur independently of baseline anxiety levels.
Dihexa: The Synaptogenic HGF Mimetic
Structure and Origin
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University by Joseph Harding’s laboratory as a derivative of angiotensin IV. It is a modified dipeptide that acts as a hepatocyte growth factor (HGF)/c-Met receptor system modulator.
Mechanism of Action
- HGF/c-Met pathway: Dihexa stabilizes the interaction between HGF and its receptor c-Met by inhibiting HGF endocytosis, effectively amplifying HGF signaling. This pathway is critical for neurite outgrowth and synapse formation (McCoy et al., 2013)
- Synaptogenesis: Promotes formation of new synaptic connections — an effect 7 orders of magnitude more potent than BDNF in cell culture assays
- Procognitive effects: Improved learning and memory in scopolamine-impaired rats and in aged rats with naturally declining cognition
Cognitive Profile
Dihexa’s unique synaptogenic mechanism produces structural neurological changes — new synaptic connections that can persist after treatment. This distinguishes it from Selank and Semax, which primarily modulate existing neurotransmission without directly building new synapses.
Three-Way Comparison Table
| Parameter | Selank | Semax | Dihexa |
|---|---|---|---|
| Type | Tuftsin analog | ACTH(4-7) analog | Ang IV derivative |
| Primary Target | GABA-A receptors | BDNF/TrkB system | HGF/c-Met pathway |
| Primary Effect | Anxiolytic | Nootropic + neuroprotective | Synaptogenic |
| Cognitive Enhancement | Indirect (anxiety reduction) | Direct (BDNF, monoamines) | Structural (new synapse formation) |
| Memory Effects | Moderate (via stress reduction) | Strong (hippocampal BDNF) | Strong (new synaptic connections) |
| Anxiety Effects | Strong anxiolytic | Mild anxiolytic | None reported |
| Neuroprotection | Moderate | Strong (ischemic stroke models) | Not primary focus |
| Administration | Intranasal | Intranasal or SC | Oral (crosses BBB) |
| Regulatory | Approved in Russia | Approved in Russia | Research compound only |
| Safety Profile | No dependence/withdrawal | Well-tolerated; extensive clinical use | Limited safety data; potency warrants caution |
Choosing the Right Nootropic Peptide
Choose Selank for:
- Anxiety-cognition interaction research
- GABAergic neurotransmission studies
- Stress resilience and performance under pressure models
- Immune-neuro crossover research (tuftsin-like immune effects)
Choose Semax for:
- Direct cognitive enhancement research
- BDNF/neuroplasticity studies
- Neuroprotection and stroke recovery models
- Monoamine neurotransmission research
- Combined with BPC-157 for neuro-regenerative protocols
Choose Dihexa for:
- Synaptogenesis and synaptic plasticity research
- Age-related cognitive decline models
- HGF/c-Met pathway investigation
- Neurodegenerative disease models (Alzheimer’s, dementia)
Frequently Asked Questions
Can these three peptides be combined?
Their non-overlapping mechanisms (GABA modulation, BDNF upregulation, synaptogenesis) suggest potential for combination research. A protocol using Selank for anxiety reduction, Semax for BDNF-mediated neuroplasticity, and Dihexa for structural synapse formation would address multiple dimensions of cognitive function simultaneously. However, no published studies have examined this specific triple combination.
Which is the most potent nootropic?
Dihexa is the most potent on a molar basis — its synaptogenic activity is reportedly 10 million times more potent than BDNF in cell culture. However, potency does not equal efficacy or safety. Semax has the most extensive clinical evidence for cognitive enhancement, with decades of use in Russia.
Is Semax or Selank better for general cognitive enhancement?
Semax is generally more appropriate for direct cognitive enhancement research, as its BDNF and monoamine effects directly improve memory, attention, and processing speed. Selank is better for situations where anxiety is the primary barrier to cognitive performance.
Conclusion
Selank vs Semax vs Dihexa represents three complementary approaches to brain research: GABAergic anxiolysis, BDNF-mediated neuroplasticity, and HGF-driven synaptogenesis. Semax offers the best balance of cognitive enhancement, neuroprotection, and clinical evidence. Explore our research peptides and research guides.
All products are sold strictly for research purposes only. Not for human consumption.